Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
The main research objective is to work out the optimal doses of the novel combination of
gemcitabine, oxaliplatin and imatinib mesylate (glivec) in patients with advanced pancreatic
cancer that has progressed during or after treatment with first-line gemcitabine.